26th Annual Biotech in Europe Forum

Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that have been too challenging to manufacture using other approaches. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, CPV-104 recombinant human complement Factor H, is in Phase 1b testing to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

Micreos is a pharmaceutical biotech based in Zug, Switzerland that discovers & develops recombinant engineered endolysin proteins that act on disease pathways in Dermatology, Oncology and Infectious disease conditions.

Our business model is focused on drug discovery & early drug development (up until clinical proof of concept) with subsequent M&A at an asset level for Phase-III development and global commercialization.
The experienced leadership team consists of a complementary blend of seasoned leaders from both big-pharma and smaller-biotech. The team has the experience and ‘knows-what-it-takes’ to bring molecules all the way through successful discovery, development, registration, reimbursement & commercialization.

AdCab is a pre-clinical, Helsinki-based biotech spinning out of Prof. Vincenzo Cerullo's IVT Lab at the University of Helsinki. It's developing a precision oncolytic adenovirus armed with a proprietary Fc Dual Engager — an engineered IgG/IgA chimeric Fc-PD-L1 fusion peptide — designed for immunosuppressive, hard-to-treat cancers (pancreatic ductal adenocarcinoma, triple-negative breast cancer, and microsatellite-stable colorectal cancer) that don't respond to any approved immunotherapy.
 
How it works: Injected directly into the tumor, the virus spares healthy tissue and converts tumor cells into biofactories that locally produce the Fc Dual Engager. This achieves two things at once — clearing the tumor's immunosuppressive cell barrier (MDSCs, TAMs) and activating a broad range of immune effector cells (NK cells, CD8+ T cells, neutrophils) — something standard checkpoint inhibitors, which only block a single axis, cannot do.
 
Evidence base: 80+ in-vitro tests, 15+ in-vivo studies and patient-derived organoids, and 5 manuscripts published in journals including JITC, Molecular Therapy: Oncolytics, and Nature Communications. Data show superior tumor control versus PD-L1 checkpoint blockade and a durable, vaccine-like memory response with no relapse on tumor re-challenge.
 
Platform potential: Built on the modular GAMER-Ad method, positioning AdCab beyond a single asset as an engine for generating new compounds against additional targets.
 
Team: Prof. Vincenzo Cerullo (Inventor, Head of Drug Discovery, Univ. of Helsinki), Dr. Firas Hamdan (Scientific Lead & Inventor), and Dr. Tuuli Ranki (Commercialization Lead, ex-Sanofi/Gilead, co-founder of Valo Therapeutics) — a team with 150+ publications and 20+ patents between them.
 
Traction: IP filed in the US, EU, and Finland; recent wins include Best Presenter at BioUK BioSeed 2026 (London) and Best Pitch at the Finnish Biotech & Investor Summit (June 2026).

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdoXLong™, a long-acting peptide platform; 3) AdOral®, an oral peptide delivery technology; and 4) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation.

Adocia holds more than 25 patent families. Based in Lyon, the Company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Pioneering the development of in vivo genetic medicines built with immune-quiet DNA.

CPTx is a leader in developing the next generation of non-viral, DNA-based in vivo CAR T cell therapies, uniquely overcoming key challenges in both oncology and autoimmune disease. CPTx’s immune-quiet proprietary DNA platform enables control over the duration of gene expression from transient to permanent, supports the co-delivery of multiple genes, and allows for repeat administration.

Curlim is a late stage preclinical  biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood.

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals.

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity.

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

ExpreS2ion is a clinical-stage biotechnology company turning precise protein engineering into immunotherapies for cancer and infectious diseases.

Our lead asset, ES2B-C001, is an active immunotherapy for HER2-positive and HER2-low breast cancer. Rather than delivering an antibody, it trains a patient's own immune system to produce a sustained anti-HER2 response. In our first-in-human Phase I trial, anti-HER2 antibody responses have been observed in all nine evaluable patients to date, with titres rising across dosing visits and holding at follow-up, and no safety signals of concern. The highest dose cohort opened in May 2026, with primary readout expected end-2026 and Phase II targeted for mid-2027.

ES2B-C001 is built on the ExpreS2™ platform, our proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle projects. Proteins made on the platform have been evaluated in clinical programmes worldwide, including partnered Phase III studies that met their primary endpoints.

ExpreS2ion develops VLP-based vaccines with AdaptVac ApS, in which it holds a 34% stake, and is listed on Nasdaq First North Growth Market (EXPRS2).

FINNCURE is a biotech company focusing on solutions for targeted therapies and targeted delivery of active pharmaceutical ingredients.

Ksilink is creating a NewCo to advance a first-in-class disease-modifying therapy for Parkinson’s disease. Built on a novel intracellular α-synuclein clearance mechanism, the program aims to address the underlying drivers of disease progression rather than symptoms alone.

The lead asset has demonstrated compelling activity in multiple patient-derived Parkinson’s disease models and encouraging early in vivo results, supported by a strong intellectual property position and a differentiated small-molecule approach.

The NewCo has been fully structured for a seamless transfer of patents, know-how, data, and development assets, providing a clear pathway toward clinical development and future partnering opportunities.

Ksilink is seeking investment partners to accelerate the program and build a leading neurodegeneration company around this innovative platform.

Oncostellae is a clinical-stage biopharmaceutical company developing OST-122, a differentiated, gut-restricted small-molecule therapy for inflammatory bowel disease.

OST-122 is an oral JAK3/TYK2/ARK5 inhibitor designed to deliver potent anti-inflammatory activity directly within the gastrointestinal tract while minimizing systemic drug exposure. This pharmacological profile seeks to capture the rapid efficacy and convenience of oral JAK inhibition while reducing the systemic safety liabilities that can limit this otherwise highly effective therapeutic class.

In a randomized, double-blind, placebo-controlled Phase IIa proof-of-concept study in patients with moderate-to-severe ulcerative colitis, OST-122 demonstrated a favorable safety and pharmacokinetic profile together with encouraging clinical activity after only four weeks of treatment. High local drug concentrations in the gastrointestinal tract combined with minimal systemic exposure provide clinical validation of its intended gut-restricted profile.

OST-122 is now positioned for further clinical development in ulcerative colitis, with the potential to establish a new therapeutic approach to IBD: powerful oral immunomodulation where it is needed, while minimizing exposure where it is not.

OxSonics is a game changing MedTech company, spun out from the University of Oxford, a Focused Ultrasound Center of Excellence. The company has developed a novel, breakthrough ultrasound-mediated drug delivery platform to significantly improve delivery of anti-cancer drugs into the target tumor site. Located in Oxford, the team is made of 7 people whose 50% are PhD.

SonoTran® is a platform comprising a proprietary ultrasound engine and Sonosensitive Particles which are co-administered and systemically infused alongside anti-cancer drugs.

OxSonics has recached a major inflection point with the completed In first‑in‑human mCRC trial , SonoTran® improved response rates (86% vs 67%), with complete responses in 4/7 patients without any device-related safety issues reported.

PharmNovo is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain, an area with significant unmet medical need. The company’s lead candidate, PN6047, is a potential first-in-class DORA (Delta Opioid Receptor Agonist) and represents a safer, non-addictive treatment for neuropathic pain.

Adularia is a preclinical-stage biotech spin-off from the University of Zurich, developing novel small-molecule cancer immunotherapies.

Through deep research into the symbiotic interplay between gut microbes and the immune system, we identified a novel therapeutic target for immuno-oncology that is predominantly expressed on tumor-residing myeloid cells. Once stimulated, these macrophages release cytokines that activate cytotoxic T-cells, leading to enhanced tumor infiltration and a potent anti-tumor effect.

Leveraging this discovery, we developed our lead candidate, a small molecule that reprograms immunosuppressive myeloid cells within the tumor microenvironment into an immunostimulatory, tumor-fighting state. This targeted, well-tolerated approach has the potential to bring immunotherapy to patients with "cold" tumors that today's treatments leave behind.

kezbio is developing a drug discovery platform for unstructured and intrinsically disordered proteins (undruggables).

We integrate fragment-based approaches with activity-based-probes and fast chemoenzymatic biocatalysis for fast and lean discovery.

Maeve Therapeutics is a Netherlands-based biotech developing non-hormonal, disease-modifying therapies for endometriosis and other women's health conditions of high unmet need. Our lead programme simultaneously targets pain, inflammation and fibrosis in endometriosis.

Meddenovo Drug Design is a Lyon-based drug design company developing cyclic peptide therapeutics for oncology and radiopharmaceuticals. The company was founded to address a fundamental bottleneck in early drug discovery: the difficulty of generating viable lead candidates for complex and hard-to-drug targets when no starting molecule exists.

Meddenovo is incubated at Bayer Life Hub, benefiting from a strong innovation ecosystem and close interaction with industry expertise. The company has raised €1.7M in total funding, combining equity and non-dilutive support. Meddenovo is also an i-Lab laureate, a highly selective French government deep-tech program that recognizes startups with high innovation potential, and significant growth prospects. Through this program, Meddenovo receives direct public funding and benefits from long-term institutional trust, reflecting national-level confidence in its technology and team.

After finalizing its pre-seed round in 2025, Meddenovo successfully achieved its planned development and business milestones. In less than two years, the company advanced its technology into a robust, ready-to-use AI platform dedicated to cyclic peptide drug design, which is now actively applied in drug discovery projects.

Meddenovo’s proprietary AI/ML-powered platform enables the de novo design and optimization of cyclic peptide drug candidates. Unlike traditional approaches that depend on prior experimental data or limited libraries, the platform allows rational exploration of a large and biologically relevant chemical space while prioritizing drug-like properties, target engagement, and functionalization potential. This makes the technology particularly well suited for oncology applications, including targeted radiopharmaceuticals.

Meddenovo advances its own internal pipeline while forming strategic partnerships with pharmaceutical companies. The company has already entered into a partnership agreement with a large pharmaceutical group, providing early industrial validation of its scientific approach and technology.

Meddenovo is currently preparing its seed financing round, planned to be finalized in 2026, to further advance its cyclic peptide pipeline and expand strategic partnerships in oncology.

Nerai develops in vivo CRISPR editors that reach mutations others cannot. A single editor treats many rare diseases, compounding small, individually unprofitable orphan indications into one scalable, blockbuster-scale asset. Our vision: no disease stays too rare to be worth a cure.